Published by Josh White on 5th September 2024
(Sharecast News) - Preclinical antibody discovery and engineering specialist Fusion Antibodies said in its final results on Thursday that despite a challenging year with a decline in revenue, it had strengthened its financial position and expanded its pipeline of opportunities.